X
DNLI icon

Xponance’s Denali Therapeutics DNLI Stock Holding History

Xponance’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$376K Buy
14,616
+1,376
+10% +$28.3K ﹤0.01% 1270
2026
Q1 		$254K Buy
13,240
+2,743
+26% +$54.6K ﹤0.01% 1361
2025
Q4 		$173K Buy
10,497
+97
+0.9% +$1.64K ﹤0.01% 1412
2025
Q3 		$151K Buy
10,400
+48
+0.5% +$690 ﹤0.01% 1396
2025
Q2 		$145K Buy
+10,352
New +$146K ﹤0.01% 1369
2024
Q4 		– Sell
-8,135
Closed -$237K – 1451
2024
Q3 		$237K Buy
+8,135
New +$202K ﹤0.01% 1163
2023
Q3 		– Sell
-6,963
Closed -$205K – 1251
2023
Q2 		$205K Buy
+6,963
New +$196K ﹤0.01% 1143
2021
Q4 		– Sell
-4,315
Closed -$218K – 1179
2021
Q3 		$218K Sell
4,315
-699
-14% -$39.4K ﹤0.01% 1102
2021
Q2 		$393K Buy
+5,014
New +$310K 0.01% 1003

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Xponance's DNLI Position: Q2 2026 in Review

Xponance increased its Denali Therapeutics (DNLI) stake by 10% in Q2 2026, buying an estimated $28.3K and bringing the position to 14,616 shares worth $376K. The position accounts for ﹤0.01% of the portfolio, ranked #1270.

Xponance first reported a position in DNLI in Q2 2021 and has held it in 9 quarters since. The position peaked at $393K in Q2 2021. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Xponance held 14,616 shares of Denali Therapeutics worth $376K as of Q2 2026.
  • Xponance bought 1,376 Denali Therapeutics shares in Q2 2026, an estimated $28.3K.
  • Denali Therapeutics made up ﹤0.01% of Xponance's portfolio in Q2 2026, its #1270 holding.
  • Xponance first reported a position in Denali Therapeutics in Q2 2021 and has held it in 9 quarters since.
  • Xponance's Denali Therapeutics position peaked at $393K in Q2 2021.
  • 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Xponance's 13F filing for Q2 2026, filed 10 Aug 2026.